Captor Therapeutics (CTX) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
11 May, 2026Executive summary
Viadrudomide (CT-01) named and progressing in trials, with positive initial results.
Vratitoclax (CT-03) nearing completion of clinical trial preparations, with clinical start planned for 2026.
Active discussions for CT-02 and research collaborations, with high likelihood of at least one partnership.
Financial highlights
Revenue from R&D services in 2025: 4,660k PLN; gross profit from sales: 1,445k PLN.
Net loss from continuing operations in 2025: -41,997k PLN; Q4 net loss: -10,046k PLN.
Total costs by type in 2025: 57,867k PLN; Q4: 12,348k PLN.
Segment performance
R&D project costs in 2025: 37,852k PLN; general management costs: 11,137k PLN.
Financial income in 2025: 1,847k PLN; financial costs: 323k PLN.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Captor Therapeutics
- R&D investments drove losses in Q1 2026, but a major capital raise secures funding into 2027.CTX
Q1 202627 May 2026 - CT-01 clinical trial advances, R&D revenue surges, and net loss narrows with strong cash reserves.CTXQ2 202411 Mar 2026
- Advancing four novel drug projects, with strong grant support and key clinical milestones ahead.CTXQ4 202411 Mar 2026
- Net loss narrowed as R&D revenue rose and clinical trial progress advanced.CTXQ3 202411 Mar 2026
- Lower R&D revenue and a net loss in Q1 2025, with key post-period events impacting outlook.CTXQ1 202511 Mar 2026
- First-in-class degraders for cancer and autoimmune diseases show strong clinical promise.CTXCorporate presentation11 Mar 2026
- Net loss widened on lower R&D revenue, but new grants and collaborations extend funding into 2026.CTXQ3 202511 Mar 2026
- Net loss widened on lower R&D revenue and higher costs, with funding secured through mid-2026.CTXQ2 202511 Mar 2026